MiNK Therapeutics Inc. (INKT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

MiNK Therapeutics Inc. (INKT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.85

0.00 (0.00%)

At close: Jan 15, 2025, 1:52 PM

undefined% (undefined)

Bid	0.83
Market Cap	33.66M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.37
PE Ratio (ttm)	-2.3
Forward PE	n/a
Analyst	Buy

Ask	0.87
Volume	66,025
Avg. Volume (20D)	93,872
Open	0.87
Previous Close	0.85
Day's Range	0.83 - 0.91
52-Week Range	0.46 - 1.90
Beta	undefined

About INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was former...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 15, 2021

Employees 31

Stock Exchange NASDAQ

Ticker Symbol INKT

Website https://minktherapeutics.com

Analyst Forecast

According to 2 analyst ratings, the average rating for INKT stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 663.81% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

8 months ago · Source

+14.31%

MiNK Therapeutics shares are trading lower. The co... Unlock content with Pro Subscription

8 months ago · Source

+8.87%

MiNK Therapeutics shares are trading higher after the company announced plans to sell securities in a private placement financing for $5.8 million. The financing is earmarked for accelerating its MiNK-215 clinical trials.

News

2 months ago · seekingalpha.com

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Jennifer Buell - President and Chief Ex...